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Bacterial vaginosis (BV) is the most prevalent alteration of vaginal microflora worldwide. BV is a polymicrobial disorder, and its
etiology is elusive. Factors predisposing to this recurrent condition are not fully characterized. We aimed to investigate whether
interleukin-1b (IL-1b) and IL-1 receptor antagonist (IL-1ra) polymorphisms are associated with BV in non-pregnant white
Italian women. Genomic DNA was obtained from 164 BV positive, and 406 control women. Two diallelic polymorphisms in the
IL-1b gene (IL-1B) representing C/T base transitions at 2511 and 13954 positions and a variable number tandem repeats
(VNTR) in intron 2 of the IL-1ra gene (IL-1RN) were assessed. We demonstrated that women who were homozygous for 2511
CC or 13954 TT of the IL-1B gene were at increased risk for BV with an odds ratio (OR) 5 1.5 [95% confidence interval
(CI) 5 1.03–2.14, P 5 0.032], and OR 5 2.8 (95% CI 5 1.37–5.88, P 5 0.004), respectively. The haplotype 2511/13954 T-C
was protective for BV, with an OR 5 0.7 (95% CI 5 0.49–0.90, P 5 0.009). The IL-1RN VNTR genotype was not associated
with BV, although the rare allele 3 showed a trend towards protection (P 5 0.049). These data show that host genetic variants
at the IL-1b locus predispose to BV among Caucasian non-pregnant women. Further studies will determine whether these
genetic polymorphisms modulate the risk for BV recurrence, and/or BV associated severe adverse outcomes as preterm birth
and human immunodeficiency virus transmission.
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Introduction
Bacterial vaginosis (BV) is the most prevalent vaginal disorder in
reproductive age women (Eschenbach, 1993; Cauci et al., 2002a).
BV is associated with several adverse outcomes, including increased
susceptibility to human immunodeficiency virus (HIV) and herpes
simplex virus type 2 (HSV-2) infections (Sewankambo et al., 1997;
Cherpes et al., 2005; Schwebbe, 2005), upper genital tract infections
(Ness et al., 2005), endometritis, post-surgical infections (Guaschino
et al., 2002), urinary tract infections and adverse pregnancy outcomes
such as spontaneous abortion, preterm delivery and low birthweight
(Hillier et al., 1995; Goldenberg et al., 2005). BV is a complex poly-
microbial disorder characterized by a decreased lactobacilli flora and a
largely increased colonization of several facultative and/or strictly
anaerobic micro-organisms, mainly Gardnerella vaginalis, Prevotella
spp., Bacteroides spp., Mobiluncus spp., Gram-positive cocci
and genital mycoplasmas (Mycoplasma hominis and Ureaplasma
urealyticum) (Eschenbach, 1993; Thorsen et al., 1998). BV has
recently been defined as a microbial/mucosal immunity disorder
(Cauci, 2004; Romero et al., 2004; Culhane et al., 2006). Factors pre-
disposing to BV remain only partially defined; in particular, reasons
for ethnic disparities in BV prevalence and for the high recurrence
rate of BV are unknown (Pereira et al., 2005; Schwebbe, 2005;
Sobel, 2005; Marrazzo, 2006). An indicator of factor(s) predisposing
to BV includes the observation that BV positive women show elevated
concentrations of vaginal interleukin-1b (IL-1b) (Cauci et al., 2002b,
2003; Cauci, 2004). IL-1b is a well-known proinflammatory cytokine,
a key mediator of the host immune response to invading micro-
organisms (Dinarello, 1996). This cytokine is able to induce the
secretion of several inflammatory factors by female reproductive
tract epithelial cells, including IL-8, tumour necrosis factor-a, IL-6
and granulocyte-macrophage colony-stimulating factor (Fortunato
et al., 1996; Wira et al., 2005). IL-1b binds the IL-1 receptor on the
surface of a variety of cells and initiates a cascade of events leading
to recruitment and activation of macrophages and neutrophils. The
activity of IL-1b is modulated by a competitive receptor antagonist
(IL-1ra). One study reported that a disproportionate increase in
vaginal levels of IL-1b over IL-1ra in women with altered bacterial
flora in mid-trimester gestation was associated with subsequent spon-
taneous preterm delivery (Genc et al., 2004b).
The genes of IL-1b (IL-1B) and IL-1ra (IL-1RN) are located close to
each other on chromosome 2 in humans (Webb et al., 1986). Poly-
morphisms in these genes correlate with altered protein expression
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in vitro (Pociot et al., 1992; Hernandez-Guerrero et al., 2003) and
in vivo (Dennis et al., 2004; Hall et al., 2004). Specific polymorphisms
in genes encoding cytokines have been associated with an increased
risk for, and worsened outcomes in many human conditions, including
infectious and inflammatory diseases (periodontal disease, gastric
cancer, hepatocellular carcinoma, rheumatoid arthritis and Alzheimer’s
disease) (El-Omar et al., 2000; Licastro et al., 2004; Pawlik et al.,
2005; Hirankarn et al., 2006; Lopez et al., 2005). Several polymorph-
isms in the IL-1B gene have been described. Among these are single-
nucleotide polymorphisms (SNPs) located at position 2511 in the
promoter region (di Giovine et al., 1992) and another SNP located at
position þ3954 in exon 5 (TaqI restriction site polymorphism desig-
nated as þ3953 in the first studies) (Pociot et al., 1992). The IL-1RN
gene has a penta-allelic polymorphic site in intron 2, containing a
variable number of 86 bp identical tandem repeats [Variable number
tandem repeat (VNTR)] (Tarlow et al., 1993).
Recently, a study performed on mostly black pregnant women found
that women with BV were less likely to be homozygous for the minor
allele (C; P ¼ 0.04) at site þ3954 IL-1B, whereas no significant find-
ings were noted for the 2511 IL-1B polymorphic site (Goepfert et al.,
2005). According to these authors, these relationships did not seem to
differ by race. Studies of associations between polymorphisms in
immune system-related genes may be confounded by allele frequency
differences between ethnic groups under examination (Pillay et al.,
2000; Tishkoff and Williams, 2002). Notably, ethnic differences
exist both in the prevalence of infections and in the extent of
immune responses to infection (Nguyen et al., 2004; Goldenberg
et al., 2005; Menon et al., 2006a). BV is 2- to 3-fold more frequent
in African-American women than in white non-Hispanic women in
the USA (Goldenberg et al., 2005; Pereira et al., 2005).
Our study determined the genotype frequencies of 2511 and
þ3954 SNPs of IL-1B, and intron 2 VNTR of IL-1RN in white
Italian women, a relatively homogeneous ethnic group. We examined
whether the polymorphisms of these genes are associated with the
occurrence of BV in non-pregnant women.
Materials and methods
Subjects and biological samples
Women were recruited during routine gynaecological examination to perform
Papanicolau test in Trieste, Italy. All women were enrolled after informed
consent according to the Institutional Ethics Committees. Inclusion criteria
were: non-pregnant Caucasian women without severe medical illnesses, no
antibiotic use in the last 2 weeks and 18 years of age. Exclusion criteria
were: presence of vaginal bleeding (because it can confound vaginal flora
assessment), yeast vaginitis (by clinical signs), Trichomonas vaginalis (evalu-
ated on a wet smear and/or Pap smear exam), Neisseria gonnorrhoeae (based
on clinical criteria confirmed by swab culture Thayer–Martin medium) and
Chlamydia trachomatis (by ligase chain reaction). Rates of sexually transmitted
infections (STIs) in this mostly middle class population as determined in
parallel studies are very low (e.g. the frequency of T. vaginalis is ,2%,
Guaschino S, unpublished). As a routine practice, at the time of scheduling
of the Pap test, patients were requested to refrain from sexual intercourse
and from any vaginal treatment for 3 days prior to their checkups. At the
visit, the provider further requested the date of the last sexual intercourse.
Women who had intercourse in the previous 3 days or who had sperm detected
in the Gram-stain smear were excluded from the study. Cases and controls were
matched by age and menopausal status.
Women with BV and healthy controls were clinically recruited using
Amsel’s criteria (Amsel et al., 1983). Vaginal specimens were collected by
sterile cotton swabs. One swab was used to create an air-dried vaginal smear
that was Gram stained and scored according to Nugent et al. (1991). For
inclusion in the BV positive group, a Nugent score of 7 or greater was used.
For inclusion in the healthy control group a Nugent score from 0 to 3 was
used. Women with intermediate flora by Gram staining were excluded from
the study. No women with BV, using Amsel’s criteria, had a Nugent score of
0–3, and no women classified as healthy by Amsel’s criteria had a Nugent
score of 7–10. A second vaginal swab was squeezed into 1 ml of sterile
saline. Samples were centrifuged at 700g for 3 min at 48C and then frozen at
2808C from the time of collection until analysis. Personnel assessing
Nugent scores and genetic polymorphisms were blinded to clinical findings.
A subset of 200 Gram-stained slides were read by a second microscopist
blinded to first readings. Concordance rate between slide evaluations was
more than 96%.
IL-1B and IL-1RN gene polymorphism identification
Genomic DNA was extracted from the swab pellet fraction according to the
standard proteinase-K digestion and ethanol extraction method. The extracted
DNA was then stored at 2208C until further analysis.
To examine the 2511 SNP, the promoter region of IL-1B was amplified by
PCR, using the primers 50-TGGCATTTGATCTGGTTCATC-30 and 50-GTTT-
AGGAATCTTCCCACTT-30 (di Giovine et al., 1992). The protocol included
35 cycles at 948C for 1 min, 558C for 30 s and 728C for 30 s and a final exten-
sion at 728C of 5 min. At the end of the procedure, the amplicons were digested
with AvaI at 378C for 3 h. Fragments were analysed after electrophoresis on
10% acrylamide gels and visualized with ethidium bromide. This gave products
of 190 and 114 bp (C allele) or 304 bp (T allele).
To determine the þ3954 SNP, the polymorphic region containing the TaqI
restriction site was amplified using the following primers: 50-GTTGTCATC-
AGACTTTGACC-30 and 50-TTCAGTTCATATGGACCAGA-30 (Bioque
et al., 1995). The 249 bp products were digested with TaqI at 658C for 1 h,
resulting in fragments that either remained intact (T allele) or were digested
into two fragments of 135 and 114 bp (C allele). The restriction fragments
were analysed by electrophoresis on 10% acrylamide gels and visualized
with ethidium bromide.
The IL-1RN intron 2 VNTR polymorphism was analysed using 50-CTC-
AGCAACACTCCTAT-30 and 50-TCCTGGTCTGCAGGTAA-30 as primers
(Tarlow et al., 1993). The PCR products of 410 bp (allele 1 ¼ 4 repeats of
the 86 bp region), 240 bp (allele 2 ¼ 2 repeats), 500 bp (allele 3 ¼ 5 repeats),
325 bp (allele 4 ¼ 3 repeats) and 595 bp (allele 5 ¼ 6 repeats) were analysed
by electrophoresis on 8% acrylamide gel stained with ethidium bromide.
Statistical analysis
Differences in clinical characteristics between cases and controls were tested
using Statistical Package for Social Sciences (SPSS). The genotype frequencies
for each polymorphism were compared between cases and controls, using,
Pearson’s chi-square or Fischer’s exact test as appropriate (also using SPSS).
The OR and the 95% confidence interval (CI) were calculated to evaluate the
genotype effects of each genotype against all others resulting in 22 compari-
sons. This approach allowed testing both dominant and recessive genetic
models of risk. The P-values for 2  n tests for each genotype were obtained
using the program R X C based on the Metropolis algorithm (Raymond and
Rousset, 1995), and available at http://www.marksgeneticsoftware.net/rxc.
htm. Testing for Hardy–Weinberg equilibrium (HWE) and allele frequency
differences were performed using tools for population genetic analysis
(TFPGA) at the same website and based on the algorithms of Raymond and
Rousset (1995). When there were deviations from HWE, we tested for geno-
type association as recommended by Sasieni (1997).
Genetic effects were also assessed using logistic regression, including clini-
cal variables that differed between cases and controls to assess whether genetic
effects are still significant after controlling for other significant variables.
Logistic regression was performed with Stataw, version 9 (StataCorp 2005).
Haplotype frequencies were estimated with the program PowerMarker (Liu
and Muse, 2005), which uses an expectation maximization (EM) algorithm
(Zhao and Sham, 2002). Haplotypes estimated to be below 3% in frequency
were not reported. Differences in the haplotype distributions between cases
and controls were determined by haplotype trend regression using this software
(Zaykin et al., 2002). The OR and CI were obtained for each haplotype in
relation to BV status using the Stataw software package. The reference distri-
bution for which all the other haplotypes were compared against was the
most common haplotype C-C.
To account for multiple testing issues, a false discovery rate (FDR) cut-off
value was calculated for each test performed and any P-value that was less
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than this cut-off is considered significant. The FDR cut-off is calculated by first
ranking all P-values from smallest to largest and then applying the formula (i/
m)q*, where i is the rank of the given P-value,m is the number of tests performed
and q* is the proportion of false positives that is acceptable. We set q* to 0.1.
Results
Of 602 subjects enrolled, 32 had intermediate vaginal flora by Gram
staining (12 were initially classified as BV and 20 as healthy by
Amsel’s criteria) and were excluded from this study. The final analysis
was performed on 570 women, including 164 (28.8%) women with
BV and 406 (71.2%) healthy controls. Demographic and behavioural
characteristics are presented in Table I. Mean age of the study popu-
lation was 37.1+ 11.2 years, 88.8% (506/570) were premenopausal
women, 11.2% (64/570) were post-menopausal women and 54.8%
(311/568) were nulliparous. Cases and controls did not differ by
age, and menopausal status. BV positive women were less likely to
use oral contraceptives or condoms, but more likely to use coitus inter-
ruptus, free intercourse, intrauterine device (IUD) or surgical steriliza-
tion than healthy controls. In addition, BV positive women were more
likely to be smokers, and less likely to be nulliparous than controls.
Study women were genotyped for the three gene loci (IL-1B in pos-
ition 2511 and þ3954; and IL-1RN intron 2 VNTR). Figure 1 shows
representative ethidium bromide stained electrophoresis gels for
2511, þ3954 IL-1B, and VNTR IL-1RN polymorphisms assessment.
One datum was not available forþ3954 genotype, and one for IL-1RN
genotype. Neither case nor control samples deviated from HWE at site
2511, but cases deviated at þ3954 of the IL-1B gene (P ¼ 0.001).
Both cases and controls deviated from HWE for the VNTR in
IL-1RN (P ¼ 0.001 for cases and P , 0.001 for controls).
Examination of the distribution of2511 IL-1B genotypes in the 570
study subjects revealed that 44.2% were homozygous CC, 44.2% het-
erozygous CT and 11.6% homozygous TT (Table II). Subjects with
BV were more likely to be homozygous for C allele at position -511
than healthy women, OR ¼ 1.488 (95% CI ¼ 1.033–2.141),
P ¼ 0.032. The two groups also differed significantly in allele fre-
quency (P ¼ 0.021). Allele and genotype distribution of IL-1B
þ3954 gene polymorphism are shown in Table III. The homozygous
CC of IL-1B þ3954 was the most common genotype in our sample of
Italian women (62.9%), the second was the CT genotype (31.6%),
followed by the TT genotype (5.4%). The differences between BV
positive women and healthy cases concerned only the TT homozygous
genotype. Women with BV exhibited a significantly higher frequency
of the TT genotype (9.8% versus 3.7%, P ¼ 0.004). This finding
resulted in an increased risk of BV for TT homozygous carriers,
with an OR of 2.837 (95% CI ¼ 1.368–5.884).
Clinical variables that might impact the association with genotype
were assessed using logistic regression. The variables that were
included in the model were oral contraceptive use, parity and
smoking. Two models were assessed; one consisting of þ3954
IL-1B with the clinical variables and the other model consisting of
2511 IL-1B with the same variables. For these models, the baseline
clinical variables were oral contraceptive use, nulliparity and non-
smoking. The baseline þ3954 IL-1B genotypes were CC and CT,
and the baseline 2511 IL-1B genotypes were CT and TT. These ana-
lyses revealed that individuals with BV were significantly more likely
to have the homozygous 2511 CC genotype than healthy women,
OR ¼ 1.579 (95% CI ¼ 1.005–2.480), P ¼ 0.047. Similar results
were seen for IL-1B þ3954 TT with OR ¼ 3.210 (95%
CI ¼ 1.362–7.564), P ¼ 0.008. In both of the logistic regression ana-
lyses, the genetic effects were still significant with OR comparable to
those without the clinical variables included.
For the IL-1RN VNTR polymorphism, only three alleles were
observed in our study; alleles 4 and 5 were not detected. In our popu-
lation, the IL-1RN*1 allele frequency was 71.7%, the second common-
est allele, IL-1RN*2, had an allele frequency of 25.9% and IL-1RN*3
had a frequency of 2.4% (Table IV). The same proportion of alleles
was observed in women with BV and healthy controls (P ¼ 0.116).
The overall distribution of IL-1RN genotypes between BV cases and
controls did not differ significantly (P ¼ 0.344). However, we
observed a trend towards decreased frequencies of cumulative 1/3,
2/3 and 3/3 genotypes in BV positive women (1.8%) compared with
healthy women (5.7%), OR ¼ 0.312 (95% CI ¼ 0.092–1.055,
P ¼ 0.048), suggesting a dominant effect of the allele 3. In addition,
allele 3 tended to be less common in BV positive women (0.9%)
compared with healthy women (3.0%, P ¼ 0.049).
Haplotype analyses were performed using all three sites as they are
relatively close on the chromosome and may interact with each other;
additionally the two sites in the IL-1B gene were examined separately
Table I. Demographic and behavioural characteristics of 570 study women
Characteristics All women n ¼ 570a BV positive n ¼ 164 Healthy controls n ¼ 406 P-value FDR cut-off
Age (years) 37.1+ 11.15b 37.9+ 10.38b 36.7+ 11.45b 0.089 0.053
Premenopausal women 506 (88.8%)c 147 (89.6%)c 359 (88.4%)c 0.770 0.092
Nulliparity 311 (54.75%)c 74 (45.7%)c 237 (58.4%)c 0.007 0.018
Sexual debut ,18 years 121/404 (27.2%)c,d 35/108 (32.4%)c,d 86/296 (29.0%)c,d 0.540 0.087
Oral contraceptive use 136/500 (27.2%)c,e 26/145 (17.9%)c,e 110/355 (31.0%)c,e 0.003 0.011
Coitus interruptus 130/500 (26.0%)c,e 50/145 (34.5%)c,e 80/355 (22.5%)c,e 0.007 0.021
Condom 125/500 (25.0%)c,e 17/145 (11.7%)c,e 108/355 (30.4%)c,e ,0.001 0.003
No sexual activityf 49/500 (9.8%)c,e 19/145 (13.1%)c,e 30/355 (8.5%)c,e 0.135 0.058
Free intercourse 43/500 (8.6%)c,e 20/145 (13.8%)c,e 23/355 (6.5%)c,e 0.013 0.029
Intrauterine device 14/500 (2.8%)c,e 9/145 (6.2%)c,e 5/355 (1.4%)c,e 0.006 0.016
Surgical sterilizationc,e 6/500 (12.0%)c,e 5/145 (3.4%)c,e 1/355 (0.28%)c,e 0.009 0.024
Smokers 139/446 (31.2%)c,g 53/120 (44.2%)c,g 86/326 (26.4%)c,g 0.001 0.008
10 or more cigarettes per day 54/446 (12.1%)c,g 26/120 (21.7%)c,g 28/326 (8.6%)c,g ,0.001 0.005
BV, bacterial vaginosis; FDR, false discovery rate.
aSome data of study women were missing, thus percentages were calculated from subjects with completed data for that question.
bAverage+ standard deviation.
cNumber (%).
dAge of sexual debut was available for 404 women, 108 BV positive and 296 healthy controls.
eContraception data were available for 500 premenopausal women, 145 BV positive and 355 healthy controls.
fVirgins or women not having sexual intercourse in the last 3 months.
gSmoking data were available for 446 women, 120 BV positive and 326 healthy controls.
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(Table V). In neither case did the haplotype frequencies differ signifi-
cantly between the groups, although the2511/þ 3954 haplotype was
almost significant (P ¼ 0.071). The haplotype T-C was in lower fre-
quency in women with BV and the OR for this haplotype relative to
the C-C haplotype was also significant, OR ¼ 0.663 (0.486–0.904),
P ¼ 0.009. This suggests that the haplotype T-C is conferring a pro-
tective effect.
Discussion
BV is present in 10–20% of white non-Hispanic women and in 30–
50% of black women (Eschenbach, 1993; Hillier et al., 1995; Cauci
et al., 2002a; Culhane et al., 2006). It is as yet an unresolved question
whether differences of BV prevalence in white and black women are
caused primarily by environmental/behavioural factors only, and/or
whether different genetic backgrounds determine the risk of BV acqui-
sition and recurrence (Russell et al., 2005; Sobel, 2005; Marrazzo,
2006). In general, BV associated alterations of the vaginal mucosal
system are only partially understood (Imseis et al., 1997; Cauci
et al., 2002b, c, 2003; Cauci, 2004; Russell et al., 2005).
Our study was performed to evaluate the SNP polymorphisms at
positions 2511 and þ3954 of the IL-1B gene, and the intron 2
VNTR polymorphism of the IL-1RN gene in non-pregnant Italian
women in relation to occurrence of BV. A similar investigation has
Figure 1. Representative electrophoresis ethidium bromide stained gels for -511 IL-1B (A), þ3954 IL-1B (B) and VNTR intron 2 IL-1RN alleles (C).
Table II. Genotype frequencies of interleukin-1b gene (IL-1B) promoter at position -511 in Italian female population, comparison of BV positive and healthy
control women
All subjects (n ¼ 570) Women with BV (n ¼ 164) Healthy women (n ¼ 406) OR (95% CI) P-value FDR cut-off
IL-1B promoter genotype (2511)
CC 252 (44.2%) 84 (51.2%) 168 (41.4%) 1.488 (1.033–2.141) 0.032 0.037
CT 252 (44.2%) 66 (40.2%) 186 (45.8%) 0.797 (0.551–1.151) 0.266 0.074
TT 66 (11.6%) 14 (8.5%) 52 (12.8%) 0.635 (0.342–1.181) 0.149 0.061
0.069 0.045
IL-1B promoter allele
Allele C 756 (66.3%) 234 (71.3%) 522 (64.3%) 0.021 0.034
Allele T 384 (33.7%) 94 (28.7%) 290 (35.7%)
OR, odds ratio.
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been performed on US black and white pregnant women by Goepfert
et al. (2005); however, that study examined, by allele-specific PCR,
polymorphisms at positions –511 and þ3954 of the IL-1B gene and
the VNTR of IL-1RN was not studied. A limitation of that study
was that it did not consider the different genetic profiles of black
and white populations separately, thereby overlapping racial groups.
We avoided this potential confounder by considering Italian women
only, a homogeneous white ethnic group.
We demonstrated that women homozygous for the genotype 2511
CC and þ3954 TT of IL-1B gene had a 1.5 and 2.8-fold, respectively,
greater risk of BV (P ¼ 0.032 and P ¼ 0.004, respectively). These
results were robust to the inclusion of clinical variables that were sig-
nificantly different between cases and controls. Our study was the first
to show that a specific haplotype of the IL-1B the 2511/þ 3954 T-C
was protective against BV (OR ¼ 0.66, 95% CI ¼ 0.49–0.90). The
effect of haplotype variation is particularly important as it has recently
been demonstrated that single SNPs alone do not provide unambigu-
ous information about IL-1B transcriptional regulation (Chen et al.,
2006). Additionally, we demonstrated that the IL-1RN had no influ-
ence on BV, with the exception of a tendency for protective effects
of the rare allele IL-1RN*3 (P ¼ 0.049). We caution that this variant
deviated from HWE in both cases and controls and may not therefore
represent a valid comparison. Explanations of this deviation from
HWE include population stratification and genotyping error. The
former is not likely given the nature of the sampled population and
the lack of deviations at the other markers. However, genotyping
cannot be eliminated as a possibility at present.
The IL-1B (2511) has been studied in several pathological con-
ditions (Hefler et al., 2002). Of note, homozygosity for IL-1B 2511
CC was associated with recurrent pregnancy loss (Wang et al.,
2006). A recent study demonstrated that the eradication rate of
Helicobacter pylori in patients with IL-1B 2511 CC was lower com-
pared with CT and TT genotypes (Sugimoto et al., 2006). IL-1B2511
CC genotype was also significantly associated with chronic hepatitis B
virus infection (Hirankarn et al., 2006). Studies of LPS stimulation of
cells in vitro and investigations in patients have demonstrated
increased production of IL-1b when the T allele is present (2511)
(Hall et al., 2004; Chan et al., 2006). Consequently, the C allele
(2511) in the promoter region should confer a limited ability to
raise IL-1b levels in response to stimuli.
The þ3954 genotype TT has been associated with a wide array of
diseases (periodontitis, rheumatoid arthritis and Alzheimer’s
disease) (Licastro et al., 2004; Lopez et al., 2005; Pawlik et al.,
2005). The findings that BV and severe periodontitis are associated
with the same polymorphism are of particular interest as some
studies demonstrated an association between BV and periodontal dis-
eases (Oittinen et al., 2005).
According to some authors, the polymorphism at þ3954 in exon 5
of the IL-1B gene contributes to an increase in IL-1b protein secretion
(Pociot et al., 1992; Hernandez-Guerrero et al., 2003; Hollegaard and
Bidwell, 2006). This observation supports the hypothesis that women
carrying hyper-responsive proinflammatory cytokine genes may over-
respond to vaginal infection secreting higher amounts of cytokines,
which may lead to pathology. However, in vitro findings of increased
IL-1b production associated with the T (þ3954) allele were not con-
firmed by in vivo findings performed in human subjects, showing a
reduced inflammatory reaction in allele T carriers (Dennis et al.,
2004). It remains controversial what effects an amino acid substitution
in the sequence of IL-1b protein can elicit. Contradictory results could
derive from the influence of the other variants in linkage with this site,
Table III. Genotype frequencies of IL-1B exon 5 at position þ3954 in Italian female population, comparison of BV positive and healthy control women
All subjects (n ¼ 569) Women with BV (n ¼ 163) Healthy women (n ¼ 406) OR (95% CI) P-value FDR cut-off
IL-1B exon 5 genotype (þ3954)
CC 358 (62.9%) 104 (63.8%) 254 (62.6%) 1.055 (0.723–1.539) 0.782 0.095
CT 180 (31.6%) 43 (26.4%) 137 (33.7%) 0.704 (0.469–1.054) 0.088 0.050
TT 31 (5.4%) 16 (9.8%) 15 (3.7%) 2.837 (1.368–5.884) 0.004 0.013
0.013 0.032
IL-1B exon 5 allele
Allele C 896 (78.7%) 251 (77.0%) 645 (79.4%) 0.393 0.079
Allele T 242 (21.3%) 75 (23.0%) 167 (20.6%)
Table IV. Genotype frequencies of interleukin-1 receptor antagonist gene (IL-1RN) in Italian female population, comparison of BV positive and healthy control
women
All subjects (n ¼ 569) Women with BV (n ¼ 163) Healthy women (n ¼ 406) OR (95% CI) P-value FDR cut-off
IL-1RN variable number tandem repeats genotype
1/1 318 (55.9%) 98 (60.1%) 220 (54.2%) 1.275 (0.881–1.844) 0.197 0.066
1/2 161 (28.3%) 42 (25.8%) 119 (29.3%) 0.837 (0.555–1.263) 0.396 0.082
1/3 19 (3.3%) 3 (1.8%) 16 (3.9%) 0.457 (0.131–1.590) 0.207 0.068
2/2 64 (11.2%) 20 (12.3%) 44 (10.8%) 1.151 (0.655–2.020) 0.625 0.089
2/3 6 (1.1%) 0 (0%) 6 (1.5%) 0.190 0.063
3/3 1 (0.2%) 0 (0%) 1 (0.2%) 1.000 0.100
1/3, 2/3 and 3/3 26 (4.6%) 3 (1.8%) 23 (5.7%) 0.312 (0.092–1.055) 0.048 0.039
0.344 0.076
IL-1RN allele
Allele 1 816 (71.7%) 241 (73.9%) 575 (70.8%) 0.116a 0.055
Allele 2 295 (25.9%) 82 (25.2%) 213 (26.2%)
Allele 3 27 (2.4%) 3 (0.9%) 24 (3.0%) 0.049b 0.042
aComparison of all three alleles.
bComparison of allele 3 versus others.
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which could be assessed by IL-1 haplotype, and/or by tissue-specific
effects, and/or depend upon the context of the stimulation (different
micro-organisms could modulate IL-1b in different ways).
It is interesting to note that the IL-1RN genotype was not associated
with BV in our study. This finding confirms a previous investigation
performed in 5 BV positive and 87 control white pregnant women per-
formed by Genc et al. (2004a). The IL1RN*2 allele has a lower fre-
quency in the black as compared with the white population (Pillay
et al., 2000; Nguyen et al., 2004; Genc et al., 2004a), thus it is a poten-
tial candidate to account for differences in innate immunity responses
between white and black ethnic groups. The IL1RN*2 has been impli-
cated in increased inflammatory responses, and it has been associated
with several pathological conditions (El-Omar et al., 2000; Gerber
et al., 2005).
Overall, our findings suggest that the association of the IL-1 geno-
type with BV does not go in the direction of an enhanced inflammatory
response genetic background, but towards a decreased IL-1 stimu-
lation. Immunity to infections at mucosal sites is likely modulated
by subtle tuning of cytokine levels, a partially diminished IL-1b rise
could hamper defenses against BV-associated micro-organisms. We
could infer that the CC (2511) and TT (þ3954) genotypes of the
IL-1B gene interact to reduce IL-1b levels and/or limit the amplifica-
tion of the IL-1b proinflammatory signals. This is consistent with our
observation that the 2511/þ 3954 T-C haplotype appears to be pro-
tective against BV. Notably, this fits with the fact that BV is not typi-
cally considered an inflammatory condition. BV positive women do
not show increased vaginal neutrophil number in comparison to
healthy women, although IL-1b levels are increased (Cauci et al.,
2003). The reduced proinflammatory cascade could derive both by
host genetic factors and/or by microbial effects (Cauci et al., 2002c;
Cauci, 2004).
In our study, we found that contraceptive and behaviour factors differ
between BV positive and healthy women. The negative association
between BV and oral contraceptive pill and condom use (Shoubnikova
et al., 1997; Calzolari et al., 2000) and the positive association between
BV and IUD use (Calzolari et al., 2000) are well documented in the lit-
erature. In addition, the association of smoking with BV was found in
several studies (Hellberg et al., 2000). In our present study, we observed
that contraceptive and behavioural factors do not modulate the IL-1 gen-
otype association with BV.
Our findings of genetic predispositions for BV in non-pregnant
women have potentially several implications. The high recurrence
rate of BV observed in some women as well as the severe adverse
outcomes associated with BV could be modulated by specific
genetic factors. On the basis of the consideration that BV affects
many million women worldwide and that BV-associated adverse out-
comes are severe conditions as preterm birth, low birth weight and
HIV transmission, genetic studies appear greatly important in this
field (Menon et al., 2006b).
A limit of our study is that we could not assess the role of the IL-1
genetic variation on gene expression or gene product levels. A strength
of our study is a well-characterized racially homogeneous European
population. On the other hand, this may limit the ability to generalize
our findings to other ethnic groups.
Further research into factors that increase women’s susceptibility to
BV will help to inform the design of vaginal microbicides/immune
modulators and other BV prevention/cure interventions.
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